Introducing: Stefanie Kammerman, Legendary Dark Pool Trader

For the 1st time ever, a former financial insider is stepping forward to show you how to spot Wall Street’s “hidden” trades before they move the market.

Wed, July 15 at 7:00PM ET
 
 
 
 

18 Biotechnology Stocks to Sell Now

18 Biotechnology Stocks to Sell Now

The ratings of 18 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Intercept Pharmaceuticals, Inc.’s (ICPT) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in earnings revisions, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of ICPT stock.

bluebird bio, Inc. (BLUE) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of BLUE stock.

Epizyme, Inc.’s (EPZM) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EPZM stock.

Advaxis, Inc. (ADXS) slips from a C to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ADXS stock.

PTC Therapeutics, Inc. (PTCT) declines this week from a D to a F. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PTCT stock.

This week, Merrimack Pharmaceuticals, Inc. (MACK) drops from a D to a F rating. Merrimack Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. The company also gets F’s in sales growth, earnings surprise, and free cash flow. For more information, get Portfolio Grader’s complete analysis of MACK stock.

Slipping from a C to a D rating, Zafgen, Inc. (ZFGN) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZFGN stock.

Cara Therapeutics Inc (CARA) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of CARA stock.

This is a rough week for Avalanche Biotechnologies Inc (AAVL). The company’s rating falls to F from the previous week’s D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AAVL stock.

Novavax, Inc. (NVAX) gets weaker ratings this week as last week’s C drops to a D. Novavax, Inc. creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle technology. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of NVAX stock.

Affimed N.V. (AFMD) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AFMD stock.

Agenus Inc. (AGEN) experiences a ratings drop this week, going from last week’s C to a D. Agenus Inc. is a biotechnology company that engages in developing and commercializing technologies to treat cancers and infectious diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGEN stock.

Aeterna Zentaris Inc. (AEZS) earns a D this week, moving down from last week’s grade of C. Aeterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with expertise in drug discovery, development and commercialization. The company also gets F’s in earnings growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AEZS stock.

Slipping from a C to a D rating, AmpliPhi BioSciences Corporation (APHB) takes a hit this week. The company also gets F’s in operating margin growth, earnings growth, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of APHB stock.

Venaxis, Inc. (APPY) gets weaker ratings this week as last week’s C drops to a D. Venaxis, Inc. develops and commercializes products for unmet diagnostic and therapeutic needs. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of APPY stock.

This week, Organovo Holdings, Inc. (ONVO) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ONVO stock.

Bio Blast Pharma Ltd. (ORPN) declines this week from a D to a F. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ORPN stock.

This is a rough week for Catalyst Biosciences, Inc. (CBIO). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CBIO stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/05/18-biotechnology-stocks-to-sell-now/.

©2020 InvestorPlace Media, LLC